Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series
Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg, Michael Deuschle
Pharmacopsychiatry December 11, 2009 DOI: 10.1055/s-0029-1237375 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case series Randomized Case report Peer reviewed |
|---|---|
| Sample size | 4 |
| Population | Four depressed patients taking standard antidepressants |
| Intervention | S-ketamine |
| Dose | 1.25 mg/kg |
| Topics | Depression Esketamine Ketamine |
| Citations | 66 |
| Key findings | Two of four depressed patients with melancholic features responded early to oral S-ketamine added to standard antidepressants and stayed in remission, while two patients with somatic symptoms, chronicity, or atypical features did not respond. The authors state the small number of patients prevents conclusions about efficacy, and suggest oral S-ketamine is well tolerated and warrants randomized controlled trials. |
Abstract
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow conclusions about efficacy. Oral S-ketamine was well tolerated and could merit being studied in randomised controlled trials due to its higher practicability compared to (S-)ketamine infusion therapy. Clinical subtyping should be considered.
Comparable studies
Other case reports and case series on esketamine for depression, most cited first.
Citations in the library
Cited by 28
- Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression American Journal of Psychiatry October 1, 2015
- Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 2018
- The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review Current Neuropharmacology November 12, 2014
- Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review Therapeutic Advances in Chronic Disease April 13, 2015
- A REVIEW OF KETAMINE ABUSE AND DIVERSION Depression and Anxiety August 1, 2016
and 23 more in the library
Cites 4
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression The World Journal of Biological Psychiatry May 12, 2008
- Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. The World Journal of Biological Psychiatry 2009
- Family History of Alcohol Dependence and Initial Antidepressant Response to an NMDA Antagonist Biological Psychiatry November 8, 2008